KPC PharmaceuticalsInc Balance Sheet Health

Financial Health criteria checks 6/6

KPC PharmaceuticalsInc has a total shareholder equity of CN¥5.7B and total debt of CN¥769.1M, which brings its debt-to-equity ratio to 13.5%. Its total assets and total liabilities are CN¥10.0B and CN¥4.3B respectively. KPC PharmaceuticalsInc's EBIT is CN¥500.8M making its interest coverage ratio -1915.5. It has cash and short-term investments of CN¥2.0B.

Key information

13.5%

Debt to equity ratio

CN¥769.10m

Debt

Interest coverage ratio	-1915.5x
Cash	CN¥2.01b
Equity	CN¥5.71b
Total liabilities	CN¥4.31b
Total assets	CN¥10.02b

Recent financial health updates

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04

Recent updates

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Nov 18

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Sep 30

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28

Financial Position Analysis

Short Term Liabilities: 600422's short term assets (CN¥7.6B) exceed its short term liabilities (CN¥4.0B).

Long Term Liabilities: 600422's short term assets (CN¥7.6B) exceed its long term liabilities (CN¥357.2M).

Debt to Equity History and Analysis

Debt Level: 600422 has more cash than its total debt.

Reducing Debt: 600422's debt to equity ratio has reduced from 17.2% to 13.5% over the past 5 years.

Debt Coverage: 600422's debt is well covered by operating cash flow (79.2%).

Interest Coverage: 600422 earns more interest than it pays, so coverage of interest payments is not a concern.

KPC PharmaceuticalsInc Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Recent updates

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.22 in 3Q 2023)

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Investor sentiment improves as stock rises 20%

New minor risk - Earnings quality

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Price target decreased by 7.1% to CN¥25.01

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Full year 2023 earnings: EPS and revenues miss analyst expectations

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

New 90-day high - CN¥11.67

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies